BRPI0715402A2 - Marcadores de doença hepática gordurosa não alcoólica (nafld) e esteatohepatite não alcoólica (nash) e métodos de uso dos mesmos - Google Patents

Marcadores de doença hepática gordurosa não alcoólica (nafld) e esteatohepatite não alcoólica (nash) e métodos de uso dos mesmos

Info

Publication number
BRPI0715402A2
BRPI0715402A2 BRPI0715402-0A2A BRPI0715402A BRPI0715402A2 BR PI0715402 A2 BRPI0715402 A2 BR PI0715402A2 BR PI0715402 A BRPI0715402 A BR PI0715402A BR PI0715402 A2 BRPI0715402 A2 BR PI0715402A2
Authority
BR
Brazil
Prior art keywords
alcoholic
stetethepatitis
nafld
nash
markers
Prior art date
Application number
BRPI0715402-0A2A
Other languages
English (en)
Inventor
Steven M Watkins
Michelle M Wiest
Rebecca A Baillie
Original Assignee
Lipomics Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipomics Technologies Inc filed Critical Lipomics Technologies Inc
Publication of BRPI0715402A2 publication Critical patent/BRPI0715402A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/02—Triacylglycerols
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0715402-0A2A 2006-08-08 2007-08-08 Marcadores de doença hepática gordurosa não alcoólica (nafld) e esteatohepatite não alcoólica (nash) e métodos de uso dos mesmos BRPI0715402A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83655506P 2006-08-08 2006-08-08
PCT/US2007/017726 WO2008021192A2 (en) 2006-08-08 2007-08-08 Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0715402A2 true BRPI0715402A2 (pt) 2013-11-26

Family

ID=39082612

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0715402-0A2A BRPI0715402A2 (pt) 2006-08-08 2007-08-08 Marcadores de doença hepática gordurosa não alcoólica (nafld) e esteatohepatite não alcoólica (nash) e métodos de uso dos mesmos

Country Status (10)

Country Link
US (2) US20100233724A1 (pt)
EP (3) EP2607902B1 (pt)
JP (1) JP2010500566A (pt)
CN (1) CN101523221A (pt)
AU (1) AU2007284733A1 (pt)
BR (1) BRPI0715402A2 (pt)
CA (1) CA2662987A1 (pt)
ES (1) ES2527438T3 (pt)
HK (1) HK1131209A1 (pt)
WO (1) WO2008021192A2 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008156662A1 (en) 2007-06-14 2008-12-24 George Mason Intellectual Properties, Inc. Methods of diagnosing non-alcoholic steatohepatitis (nash)
WO2009059150A2 (en) * 2007-11-02 2009-05-07 Metabolon, Inc. Biomarkers for fatty liver disease and methods using the same
FI122252B (fi) * 2008-01-04 2011-10-31 Valio Oy Koostumus maksa-aineenvaihdunnan parantamiseksi ja diagnostinen menetelmä
EP3059592A1 (en) * 2008-05-28 2016-08-24 Basf Se Methods for assessing liver toxicity
JPWO2009151125A1 (ja) * 2008-06-13 2011-11-17 持田製薬株式会社 肝障害の診断及び治療
EP2313782B1 (en) 2008-07-03 2012-08-29 One Way Liver Genomics, S.L. Proteomic fingerprint for the diagnosis of non-alcoholic steatohepatitis (nash) and/or steatosis
JP2011528117A (ja) * 2008-07-15 2011-11-10 メタノミクス ヘルス ゲーエムベーハー 胃バイパス及びそれに関連する状態を診断する手段及び方法
EP2157431A1 (en) 2008-08-11 2010-02-24 One Way Liver Genomics, S.L. Method for the diagnosis of NASH using metabolic profiles
JP5403581B2 (ja) * 2008-09-02 2014-01-29 国立大学法人 岡山大学 ５−ｈｅｔｅを含有する抗ｈｃｖ剤およびその利用
JP5322556B2 (ja) * 2008-09-19 2013-10-23 株式会社Ｍｃｂｉ 新規非アルコール性脂肪性肝疾患バイオマーカーおよび該バイオマーカーを用いた非アルコール性脂肪性肝疾患の検出方法
US20110313276A1 (en) 2008-11-18 2011-12-22 Centre Hospitalier Universitaire D'angers Non-invasive in vitro method for quantifying liver lesions
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US11835503B2 (en) * 2009-05-28 2023-12-05 The Cleveland Clinic Foundation TMA-formation inhibitor treatment for elevated TMA-containing compound diseases
EP2309276A1 (en) 2009-09-22 2011-04-13 One Way Liver Genomics, S.L. Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
JP2013509588A (ja) * 2009-10-29 2013-03-14 テシス バイオサイエンス， インコーポレイテッド ２型糖尿病の予防に対して一貫した改善をもたらすタンパク質バイオマーカーおよび脂質代謝物バイオマーカー
WO2011140093A2 (en) * 2010-05-03 2011-11-10 The Cleveland Clinic Foundation Detection and monitoring of nonalcoholic fatty liver disease
EP2385374B2 (en) * 2010-05-05 2018-02-28 Zora Biosciences OY Lipidomic biomarkers for atherosclerosis and cardiovascular disease
US9140686B2 (en) * 2010-06-10 2015-09-22 Metanomics Health Gmbh Biomarkers for diagnosing liver disease
US9541565B2 (en) 2011-04-08 2017-01-10 Zora Biosciences Oy Biomarkers for sensitive detection of statin-induced muscle toxicity
CN103502820B (zh) * 2011-04-08 2016-09-07 佐拉生物科学公司 用于他汀引发的肌肉毒性的灵敏检测的生物标志物
WO2012143514A1 (en) * 2011-04-20 2012-10-26 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Method for the diagnosis of liver injury based on a metabolomic profile
EP2810079A4 (en) * 2012-01-31 2015-08-05 Teknologian Tutkimuskeskus Vtt Oy PROCESS FOR DETERMINING THE LIVERY QUANTITY OF LIQUID AND METHOD FOR DIAGNOSIS OF NAFLD
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
JP2016538288A (ja) 2013-11-15 2016-12-08 ディグニティ サイエンシス リミテッド 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
ES2732310T3 (es) 2013-12-10 2019-11-21 Univ California Diagnóstico diferencial de enfermedad hepática
US20170184613A1 (en) * 2014-05-23 2017-06-29 Georgetown University Exosome and lipid biomarkers for memory loss
CN104280477B (zh) * 2014-11-03 2016-03-30 天津中医药大学 内源性小分子物质在快速检测肝毒性方面的应用
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
KR102510365B1 (ko) * 2015-02-13 2023-03-15 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 비-알코올성 지방 간 질병을 확인하기 위한 방법 및 조성물
JPWO2016163539A1 (ja) * 2015-04-10 2018-04-19 社会福祉法人恩賜財団済生会 肝疾患の病態を判別する方法
ES2851525T3 (es) 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
MX2021000773A (es) 2015-12-18 2022-07-19 Afimmune Ltd Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo.
WO2017167821A1 (en) * 2016-03-29 2017-10-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lipid biomarkers and compositions
JP7036805B2 (ja) * 2016-05-29 2022-03-15 深▲じぇん▼市▲絵▼云生物科技有限公司 肝疾患関連バイオマーカーおよびその使用方法
WO2018007422A1 (en) 2016-07-05 2018-01-11 One Way Liver,S.L. Identification of human non-alcoholic fatty liver disease (nafld) subtypes
EP3267199A1 (en) 2016-07-06 2018-01-10 One Way Liver S.L. Diagnostic methods based on lipid profiles
JP2016191718A (ja) * 2016-07-27 2016-11-10 ゾラ バイオサイエンシーズ オサケ ユキチュア スタチン誘発性筋毒性の高感度検出のためのバイオマーカー
CN107952083B (zh) * 2016-10-14 2021-12-03 复旦大学附属华山医院 脂代谢相关分子urg4或urgcp及其应用
US10548710B2 (en) 2017-02-24 2020-02-04 The Cleveland Clinic Foundation Method and apparatus for time-differential deployment of an endovascular device within a body lumen
CN110947003B (zh) * 2017-08-21 2021-04-02 武汉大学 Gpr31抑制剂在制备治疗肾脏缺血再灌注损伤及相关疾病药物中的应用
CN111065748B (zh) * 2017-09-18 2024-04-09 基恩菲特公司 非酒精性脂肪性肝病、非酒精性脂肪性肝炎和/或肝纤维化的非侵入性诊断
EP3502703A1 (en) 2017-12-22 2019-06-26 Metanomics Health GmbH Method for the assessment of nafld
WO2019164962A1 (en) * 2018-02-20 2019-08-29 EMULATE, Inc. Human microphysiological cell system for liver disease conversion with prov 1-18585 and prov 2-19154
CN108932976A (zh) * 2018-06-11 2018-12-04 西安医学院 一种非酒精性脂肪性肝病无创性诊断程序
WO2020044497A1 (ja) * 2018-08-30 2020-03-05 国立大学法人 東京大学 Ｎａｆｌｄ又はｎａｓｈの検出又はリスクの予測方法、ｎａｆｌｄ又はｎａｓｈを検出するための診断薬キット、対象における肝線維化の進行度の判定方法、及び対象における肝線維化の進行度を判定するための診断薬キット
WO2020044500A1 (ja) * 2018-08-30 2020-03-05 国立大学法人 東京大学 脂肪性肝疾患の検出又はリスクの予測方法、脂肪性肝疾患を検出するための診断薬キット及びバイオマーカー、対象の肝線維化の進行度の判定方法、並びに対象の肝線維化の進行度を判定するためのバイオマーカー
WO2020066162A1 (ja) * 2018-09-26 2020-04-02 株式会社島津製作所 非アルコール性脂肪肝疾患の検出方法、非アルコール性脂肪肝疾患検出用キットおよび非アルコール性脂肪肝疾患検出用バイオマーカー
WO2020073000A1 (en) * 2018-10-05 2020-04-09 The Regents Of The University Ofcalifornia Methods and compositions for determination of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash)
KR102105880B1 (ko) * 2018-10-26 2020-04-29 서울대학교병원 비알코올 지방간 질환의 조직학적 중증도 진단 또는 예후 측정에 관한 정보 제공 방법
JP6592627B1 (ja) * 2019-03-12 2019-10-16 国立大学法人 東京大学 Ｎａｆｌｄ又はｎａｓｈの検出又はリスクの予測方法、ｎａｆｌｄ又はｎａｓｈを検出するための診断薬キット、対象における肝線維化の進行度の判定方法、及び対象における肝線維化の進行度を判定するための診断薬キット
JP6592628B1 (ja) * 2019-03-12 2019-10-16 国立大学法人 東京大学 脂肪性肝疾患の検出又はリスクの予測方法、脂肪性肝疾患を検出するための診断薬キット及びバイオマーカー、対象の肝線維化の進行度の判定方法、並びに対象の肝線維化の進行度を判定するためのバイオマーカー
CN112433012A (zh) * 2020-11-23 2021-03-02 华南农业大学 一种鸡肉品质脂肪酸评价模型的构建方法及应用
DE102022131674A1 (de) 2022-11-30 2024-06-06 Universitätsklinikum Jena, Körperschaft des öffentlichen Rechts Diagnose von Metabolischen Veränderungen der Leber mittels metabolischer Analyse von Erythrozyten durch Massenspektrometrie
CN115876935B (zh) * 2022-12-29 2023-11-14 大连博源医学科技有限公司 一种用于检测血液中11-脱氢血栓烷b2的液相色谱-串联质谱方法和试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002320316A1 (en) 2001-07-06 2003-01-21 Lipomics Technologies, Inc. Generating, viewing, interpreting, and utilizing a quantitative database of metabolites
CA2459508A1 (en) * 2001-09-24 2003-04-03 Lipomics Technologies, Inc. Methods of using quantitative lipid metabolome data
US20040024065A1 (en) * 2002-03-11 2004-02-05 Watkins Steven M. Novel metabolic targets and markers
EP1739431A4 (en) * 2004-04-23 2008-10-15 Ajinomoto Kk METHOD FOR ASSESSING NON-ALCOHOLIC STEATOHEPATITIS
AU2005284830A1 (en) * 2004-09-13 2006-03-23 Lipomics Technologies, Inc. Metabolite markers for weight management
HUE026057T2 (en) * 2006-05-09 2016-05-30 Genzyme Corp Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis

Also Published As

Publication number Publication date
EP3285072A1 (en) 2018-02-21
EP2057473A4 (en) 2009-09-02
US20100233724A1 (en) 2010-09-16
JP2010500566A (ja) 2010-01-07
US20200116743A1 (en) 2020-04-16
CA2662987A1 (en) 2008-02-21
AU2007284733A1 (en) 2008-02-21
WO2008021192A2 (en) 2008-02-21
EP3285072B1 (en) 2020-04-15
EP2057473A2 (en) 2009-05-13
WO2008021192A3 (en) 2008-11-06
CN101523221A (zh) 2009-09-02
ES2527438T3 (es) 2015-01-26
EP2607902A1 (en) 2013-06-26
HK1131209A1 (en) 2010-01-15
EP2607902B1 (en) 2017-10-04
EP2057473B1 (en) 2014-11-12

Similar Documents

Publication Publication Date Title
BRPI0715402A2 (pt) Marcadores de doença hepática gordurosa não alcoólica (nafld) e esteatohepatite não alcoólica (nash) e métodos de uso dos mesmos
DK2840131T3 (da) Fremstilling af fedtsyrer og derivater deraf
DE602005013779D1 (de) Gewebebiopsiegerät
FI20060449A (fi) Mammografiamenetelmä ja mammografialaite
EP1949105A4 (en) MARKERS ASSOCIATED WITH DIABETES AND METHODS OF USE THEREOF
BRPI0716354A2 (pt) "composiÇço e mÉtodo"
DE602004002201D1 (de) Dispergierbare pharmazeutische zusammensetzung eines entzündungshemmers
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
BRPI0807495A2 (pt) Adjuvantes e métodos de emrpego dos mesmos
PT2592072T (pt) Inibidores de proteína tirosina fosfatase humana e sua utilização
DE602005020738D1 (de) Ultraschallsonde
IL196129A0 (en) Human protein tyrosine phosphatase inhibitors and methods of use
ZA200900558B (en) Human protein tyrosine phosphatase inhibitors and methods of use
SE0600870L (sv) Detekteringsanordning och förfarande
BRPI0813355A2 (pt) Compostos de quinazolinona e métodos de uso dos mesmos
BRPI0808054A2 (pt) análogos de indenoisoquinolinona e métodos de uso dos mesmos
BRPI0810606A2 (pt) Agentes de liberação de dispositivo de implante e métodos de uso dos mesmos
DE602005015858D1 (de) Ultraschallsonde
BRPI0719997A2 (pt) Uso de epotilonas no tratamento de osteoporose e doenças relacionadas
BRPI0717202A2 (pt) emulsço edÍvel e usos
ZA200900492B (en) Human protein tyrosine phosphatase inhibitors and methods of use
DK1926499T3 (da) Anvendelse af terapeutisk virksomme lipider samt fremgangsmåde til fremstilling af organ-/vævs-specifikke terapeutisk virksomme lipider
ITMI20042099A1 (it) Estratti di trifoglio per la preparazione di agenti anti-afidi
SE0501590L (sv) Anordning och förfarande
ES1062411Y (es) Recogedor de excrementos y/o objetos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2479 DE 10-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.